A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy.

IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Phillip H Kuo, Don C Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A Weber, Wolfgang P Fendler, Michael S Hofman, Bernd J Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M Catafau, Ayse T Kendi
{"title":"A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.","authors":"Phillip H Kuo,&nbsp;Don C Yoo,&nbsp;Ryan Avery,&nbsp;Marc Seltzer,&nbsp;Jeremie Calais,&nbsp;James Nagarajah,&nbsp;Wolfgang A Weber,&nbsp;Wolfgang P Fendler,&nbsp;Michael S Hofman,&nbsp;Bernd J Krause,&nbsp;Marcia Brackman,&nbsp;Euloge Kpamegan,&nbsp;Samson Ghebremariam,&nbsp;Taylor Benson,&nbsp;Ana M Catafau,&nbsp;Ayse T Kendi","doi":"10.2967/jnumed.122.265077","DOIUrl":null,"url":null,"abstract":"<p><p>[ <sup>68</sup>Ga]Ga-PSMA-11 ( <sup>68</sup>Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)-positive tumors on PET scans. In the VISION study, <sup>68</sup>Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of <sup>68</sup>Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. <b>Methods:</b> In VISION, <sup>68</sup>Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. <b>Results:</b> For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50-0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38-0.71), 0.67 (95% CI, 0.52-0.83), and 0.59 (95% CI, 0.43-0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49-0.99), 0.76 (95% CI, 0.46-0.99), and 0.89 (95% CI, 0.67-0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66-0.85) for reader 1, 70 of 88 (0.80; 0.70-0.87) for reader 2, and 73 of 96 (0.76; 0.66-0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. <b>Conclusion:</b> Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for <sup>68</sup>Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2967/jnumed.122.265077","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 2

Abstract

[ 68Ga]Ga-PSMA-11 ( 68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)-positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50-0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38-0.71), 0.67 (95% CI, 0.52-0.83), and 0.59 (95% CI, 0.43-0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49-0.99), 0.76 (95% CI, 0.46-0.99), and 0.89 (95% CI, 0.67-0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66-0.85) for reader 1, 70 of 88 (0.80; 0.70-0.87) for reader 2, and 73 of 96 (0.76; 0.66-0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.

Abstract Image

Abstract Image

Abstract Image

68Ga-PSMA-11 PET/CT扫描解读读者协议的视觉亚研究,以确定患者是否适合177Lu-PSMA-617放射配位治疗。
[68Ga]Ga-PSMA-11 (68Ga-PSMA-11)用于PET扫描识别前列腺特异性膜抗原(PSMA)阳性肿瘤。在VISION研究中,68Ga-PSMA-11被用于确定转移性去势抵抗性前列腺癌患者是否有资格接受[177Lu]Lu-PSMA-617 (177Lu- psma -617)治疗,基于预定义的阅读标准。本子研究旨在探讨68Ga-PSMA-11 PET/CT扫描使用VISION读取标准的视觉评估的解读器变异性和解读器内再现性,并评估本研究和VISION研究的读取结果之间的一致性。方法:在VISION中,68Ga-PSMA-11 PET/CT扫描集中读取至少1个psma阳性病变,无符合排除标准的psma阴性病变作为纳入病例。在本亚研究中,从VISION中随机选择125个PET/CT扫描(75个纳入病例和50个排除病例),并由3个独立的中心阅读器进行回顾性评估。随机选取20例(12例纳入病例和8例排除病例)重新编码,以评估阅读器内再现性。将病例分类为纳入病例或排除病例是基于VISION阅读标准。采用Fleiss κ-统计方法评估解读器总体变异性,采用Cohen κ-统计方法评估解读器两两变异性和解读器内再现性。结果:对于翻译的可变性,读者同意77%的案例(总体平均同意率,0.85;Fleiss κ, 0.60 [95% CI, 0.50-0.70])。两两一致率分别为0.82、0.88和0.84,对应的Cohen κ分别为0.54 (95% CI, 0.38-0.71)、0.67 (95% CI, 0.52-0.83)和0.59 (95% CI, 0.43-0.75)。在阅读器内再现性方面,一致性为0.90、0.90和0.95,对应的Cohen κ分别为0.78 (95% CI, 0.49-0.99)、0.76 (95% CI, 0.46-0.99)和0.89 (95% CI, 0.67-0.99)。在本子研究中被纳入的病例总数中,实际纳入VISION的病例数为93例中的71例(一致性率,0.76;读者1的95% CI, 0.66-0.85), 88人中有70人(0.80;0.70-0.87), 96个读者中有73个(0.76;0.66-0.84)。所有读者都同意75个VISION纳入案例中的66个。结论:使用VISION读取标准对68Ga-PSMA-11 PET/CT扫描进行评估,观察到中等至基本的解读器一致性和基本至几乎完美的解读器内再现性。在VISION中应用的读取规则可以很容易地学习,并且具有良好的再现性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Nuclear Medicine
Journal of Nuclear Medicine 医学-核医学
CiteScore
13.00
自引率
8.60%
发文量
340
审稿时长
1 months
期刊介绍: The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信